Foundation News

NEW YORK, NY – The Crohn’s & Colitis Foundation announced today that it was selected as one of two patient organizations to participate in an U.S.

 

NEEDHAM, Mass., Aug. 28, 2019 /PRNewswire/ -- The Crohn's & Colitis Foundation's New England Chapter proudly announces its 50th anniversary, commemorating five decades of volunteer leadership, research initiatives, disease awareness, patient support, and advocacy programs.

Check out our September 2019 Chapter Newsletter

Check out our August 2019 Chapter Newsletter

The Greater San Diego & Desert Area Chapter is excited to announce that McKenna Plant has joined our team as our new California Education Manager!

Read our June 2019 Chapter Newsletter

NEW YORK, NY – The cost of care for inflammatory bowel disease (IBD) in the United States has increased significantly over the past five years, according to the results of the Crohn’s & Colitis Foundation’s cost of care study.

NEW YORK, NY – Today, the Crohn’s & Colitis Foundation released its new five-year research agenda to address unmet needs in the inflammatory bowel disease (IBD) research community and provide a roadmap for not only the Foundation but also the IBD research community at-large.

#PartyWithAPurpose: This isn’t your average group of ladies who lunch.

CAMBRIDGE, England—PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced details of a jointly sponsored study with the US Crohn’s & Colitis Foundation.

Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel disease (IBD), which may affect as many as 3 million Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.